Steven Romano
Vermogen: 23 387 $ op 30-11-2025
Vermogen: 23 387 $ op 30-11-2025
Steven Joseph Romano is currently Chairman at National Pharmaceutical Council since 2021, Director at Evolution Research Group LLC, Independent Director at Dianthus Therapeutics, Inc. since 2024, and Chief Research & Development, Executive VP at Silence Therapeutics Plc since 2019.
Former roles include Senior VP & Head-Global Medicines Development at Pfizer Inc. from 1999 to 2015, Chief Scientific Officer & Executive VP at Keenova Therapeutics Plc from 2015 to 2022, Chief Scientific Officer & Executive VP at Mallinckrodt Pharmaceuticals Ltd. from 2015 to 2022, and President of the International Society For CNS Clinical Trials & Methodology.
Education includes undergraduate studies at Washington University in St. Louis and a doctorate from the University of Missouri School of Medicine.
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
| 31-03-2026 | 12.993 ( 0,01% ) | 23 387 $ | 30-11-2025 | |
| 21-05-2026 | 0 ( -.--% ) | - $ | 31-05-2026 |
| Bedrijven | Functie | Begin |
|---|---|---|
| SILENCE THERAPEUTICS PLC | Hoofd Techniek/Wetenschap/O&O | 01-04-2023 |
| DIANTHUS THERAPEUTICS, INC. | Directeur/Bestuurslid | 16-09-2024 |
National Pharmaceutical Council
National Pharmaceutical Council Miscellaneous Commercial ServicesCommercial Services Operates as a not for profit organization which specializes in research development, information dissemination, education and communication of information to patients | Voorzitter | 04-11-2021 |
Evolution Research Group LLC
Evolution Research Group LLC Miscellaneous Commercial ServicesCommercial Services Provides clinical research services | Directeur/Bestuurslid | - |
| Bedrijven | Functie | Einde |
|---|---|---|
| MALLINCKRODT PLC | Hoofd Techniek/Wetenschap/O&O | 31-12-2022 |
Mallinckrodt Pharmaceuticals Ltd.
Mallinckrodt Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Manufactures pharmaceutical products | Hoofd Techniek/Wetenschap/O&O | 01-12-2022 |
| PFIZER INC. | Corporate Officer/Principal | 01-05-2015 |
International Society For Cns Clinical Trials & Methodology | President | - |
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
| Bedrijven in privébezit | 10 |
|---|---|
Pfizer Inc.
Pfizer Inc. Pharmaceuticals: MajorHealth Technology Engages in discovery, development, manufacturing, marketing, sale and distribution of biopharmaceutical products & ingredients | Health Technology |
Washington University in St. Louis
Washington University in St. Louis Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Keenova Therapeutics Plc
Keenova Therapeutics Plc Pharmaceuticals: MajorHealth Technology Provides pharmaceutical products | Health Technology |
Silence Therapeutics Plc
Silence Therapeutics Plc Miscellaneous Commercial ServicesCommercial Services Engages in the research and development of novel pharmaceutical products | Commercial Services |
National Pharmaceutical Council
National Pharmaceutical Council Miscellaneous Commercial ServicesCommercial Services Operates as a not for profit organization which specializes in research development, information dissemination, education and communication of information to patients | Commercial Services |
University of Missouri School of Medicine
University of Missouri School of Medicine Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Evolution Research Group LLC
Evolution Research Group LLC Miscellaneous Commercial ServicesCommercial Services Provides clinical research services | Commercial Services |
Mallinckrodt Pharmaceuticals Ltd.
Mallinckrodt Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Manufactures pharmaceutical products | Health Technology |
International Society For Cns Clinical Trials & Methodology | |
Dianthus Therapeutics, Inc.
Dianthus Therapeutics, Inc. BiotechnologyHealth Technology Develops therapeutics for patients with autoimmune and inflammatory diseases | Health Technology |
Kies jouw editie
Alle financiële informatie op nationaal niveau